R&D News | pharmaphorum

News

Study links Ozempic/Wegovy to sight-threatening disorder

Shares in Novo Nordisk and Eli Lilly have been under pressure after a study emerged suggesting that people taking a GLP-1 agonist had an elevated risk of a rare but serious eye condition.

News

Beacon lights up with $170m for retinal disease gene therapy

UK-headquartered Beacon Therapeutics has raised a whopping $170 million in second-round financing that will be used to advance a gene therapy for an inherited cause of blindness through a p

News

GSK goes all-in on CureVac’s mRNA vaccines

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and

News

Advantage J&J in multiple myeloma CAR-T tussle with BMS

Johnson & Johnson and partner Legend Biotech are celebrating a big win in their efforts to expand the use of CAR-T therapy Carvykti for multiple myeloma, after showing a survival benefi

News

Radionetics Oncology's chief executive Paul Grayson

Lilly builds in radiopharma with $140m Radionetics deal

Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outr

News

NeuroSense says ALS drug extends survival

NeuroSense Therapeutics is currently facing de-listing from the Nasdaq, so encouraging data from a phase 2b trial of its PrimeC drug candidate for amyotrophic lateral sclerosis (ALS) comes

Study links Ozempic/Wegovy to sight-threatening disorder

Beacon lights up with $170m for retinal disease gene therapy

GSK goes all-in on CureVac’s mRNA vaccines

Advantage J&J in multiple myeloma CAR-T tussle with BMS

Lilly builds in radiopharma with $140m Radionetics deal

NeuroSense says ALS drug extends survival

Novartis CEO joins board of "responsible" AI firm Anthropic

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks